Wealthpress

Wealthpress

Cytodyn Phase 2b/3 Trial Results Expected Any Day

Posted: 04 Feb 2021 09:53 AM PST

Cytodyn Inc (OTCMKTS:CYDY), a late-stage biotech drug developer, has already delivered a win for Wealthpress subscribers from our first feature back in April this year.  Billions have been invested into hundreds of biotechs all competing to produce a cure or treatment for severe COVID-19 instances that cause death, and none have succeeded. Except Cytodyn, if early indications are confirmed in the current trial now underway.

But after a deep dive on the company's financial statements and SEC filings, a picture emerges of company management working with a "toxic lender" to funnel severely discounted shares to the lender regularly.  An investment in Cytodyn is a purely speculative bet on my part, and if the expected upward price movement does not occur after results in the company's phase 2b/3 trial for severe-to-critical COVID-19, I will exit the investment.

If the company's drug does in fact reliably save lives in severe-to-critical COVID19 patients, then a groundswell of investor support could push the company into new, higher-grade relationships, which would allow for the redemption of debentures and elimination of reliance on fly-by-night financings such as those described below.

Cytodyn's sole focus is developing therapies based on a monoclonal antibody called "leronlimab", technically described as "humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)". This engineered antibody was purchased from Progenics Pharmaceuticals as "PRO 140", a recently-acquired subsidiary of Lantheus Holdings Inc (NASDAQ:LNTH), back in 2012.

Total cost of acquisition amounts to $10 million plus a 5% net royalty on commercial sales.

The drug was acquired on its early promise as an HIV treatment, for which continued development and research by Cytodyn has demonstrated the ability to reduce daily drug cocktails with myriad pills into a single monthly injection, in some cases, with zero side effects. To date, the FDA has denied Cytodyn's Biologics License Application (BLA)

Since then, Cytodyn's scientific team has found the antibody's effect on the CCR5 receptor has extremely positive therapeutic implications for everything from certain solid tumours to NASH (Non-alcoholic steatohepatitis), the liver function ailment that afflicts up to 12 percent of the US population, and up to 26% globally.

But the real emergent and potentially transformational application for leronlimab, as stated at the beginning, (which is now being branded as Vyrologix by Cytodyn), is for the Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19 that precludes the Sequential Organ Failure in fatal instances of COVID infections.

Leronlimab apparently blocks the CCR5 receptor from over-responding to the virus and launching the now household-word "cytokine storm". Some proportion of patients apparently return from the brink after 2 treatments (and in some cases, 1 treatment) of leronlimab, even if intubated.

The company completed enrollment of a phase 2b/3 trial on December 15 to "evaluate the efficacy and safety of leronlimab for patients with severe-to-critical COVID-19 indications is a two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study," according to the company's press release.

This trial period concluded on January 12-ish, and if the results are positive, this will make leronlimab a top treatment for ARDS.

While the vaccines that are currently circulating are definitely lending hope for a normalization of society by mid-2021, the surging global rates of infection mean the immediate future is already overwhelming health care systems around the world as more and more people require access to Intensive Care Unit hospitalization.

During my first interview with Dr. Nader Pourhassan back in March of 2020, his extreme enthusiasm for the prospects of this drug's effectiveness was evident.

This was before the now raging second wave had gathered steam, and he was then seeing patients who were receiving leronlimab under the FDA's Emergency Investigative New Drug exemption.

At the time, though, this small independent biotech with no major funding and a decidedly unfortunate public listing on the naked short-sellers' dream OTC marketplace was getting ready to apply for a listing on NASDAQ, and the deck was stacked against it.

Full Disclosure: I own 10,000 shares at an average cost of $6.23

While the world focuses breathlessly on the hope for a new vaccine to regain their social liberties, the 10-ish percentage of COVID infectees who descend into the cytokine storm-driven ARDS literally have their lives saved by this apparently versatile drug. For them, a vaccine is literally pointless.

This drug has "blockbuster potential" written all over it.

With 394 patients enrolled in the Phase 2b/3 trial as of December 16, and first data expected this week, any demonstrable consistency in the data is going to capture the world's attention in the most profound way. Short sellers could be swept aside (at least temporarily) as the company's new share price levels qualify it for NASDAQ listing.

Cytodyn management says it has 700,000 doses ready for sale now, with an additional 2.5 million ordered for each of 2021 and 2022 in a manufacturing agreement with Samsung, according to its CEO.

The Downside

So if leronlimab/PRO 140/Vyrologix is so great, how come the stock's been stuck in sub-$5 penny stock purgatory for so long?

The quick answer is "OTC".

Besides struggling with a share price under $3, the company has not been able to meet and maintain certain other quantitative requirements, like positive shareholders' equity of at least $5 million.

But in the NASDAQ world, there are non-quantifiable behaviours by companies that cause delays to NASDAQ listings. Overtly promotional communications are among such criteria that will never result in a refusal letter…nor a NASDAQ listing.

More importantly, Cytodyn has also not been able to access capital under conventional means, thanks to its being listed on the OTC, and therefore un-attractive on that basis alone to white shoe firms.

So, they have been reduced to accepting shareholder-hostile OID debentures with ugly conversion terms that create a short-seller's wet dream.

In November, they borrowed 28.5 million from Streeterville Capital of which only $25 million was paid to the company; $3.4 million is the discount the Streeterville pockets, and $100k is set aside to cover the expenses. Streeterville is associated with Illiad Trading and Research, which is controlled by John Fife of Chicago Ventures Inc. Iliad has been called a "legendary so-called toxic lender", by rival research firm Utopia Capital Research.

Under the terms of the deal, Cytodyn has to pay back $7.5 million a month. If they don't have the cash, they pay in stock; most recently, at a conversion price of $3.40 a share.

Now just imagine if you're an opportunistic low-rent lender and you've got a guaranteed 2.2 million shares coming your way in the first week of each month. Any price above the conversion price is pure profit. Remember – this guy isn't an investor; he's a lender.

He's not operating on the expectation that Cytodyn stock could go parabolic if leronlimab is deemed a cure for ARDS; his business model is to limit risk and maximize upside through discounted conversion of share.

This is the short seller's wet dream I'm talking about. Not only is the lender enticed to go short, but any short-trading bucket shop in town who can fog a mirror and read an EDGAR filing know that every month, like clockwork, there's going to be 2 million+ shares hitting the bid down to $3.40.

The SEC is not impressed, and on September 3, 2020, filed a complaint.

The Securities and Exchange Commission today filed charges against John M. Fife of Chicago and companies he controls for acquiring and selling more than 21 billion shares of penny stock without registering as a securities dealer with the SEC.

The SEC's complaint, alleges that between 2015 and 2020, Fife, and his companies, Chicago Venture Partners, L.P., Iliad Research and Trading, L.P., St. George Investments LLC, Tonaquint, Inc., and Typenex Co-Investment, LLC, regularly engaged in the business of purchasing convertible notes from penny stock issuers, converting those notes into shares of stock at a large discount from the market price, and selling the newly issued shares into the market at a significant profit. The SEC alleges that Fife and his companies engaged in more than 250 convertible transactions with approximately 135 issuers, sold more than 21 billion newly-issued penny stock shares into the market, and obtained more than $61 million in profits.

Streeterville Capital is not mentioned as an entity in the complaint. Which suggests that it was likely used by Fife and Cytodyn to avoid detection by the SEC that this same scheme was being perpetrated on Cytodyn at the time of its complaint.

But that's not the only reason the stock can't maintain any upward momentum.

The company has been selling stock privately at ridiculously low prices, to the point where one wonders just who exactly are the lucky winners of what amounts to free millions of dollars?

To wit:

In addition, beginning in the month of November 2020 and for each of the following five (5) calendar months thereafter, the Company is obligated to reduce the outstanding balance of the Note by $7,500,000 per month (the "Debt Reduction Amount"). Payments the Company makes under the Prior Notes will be credited toward the payment of each monthly Debt Reduction Amount. The Debt Reduction Amount payments are not be subject to the 15% prepayment premium.

Also detracting from the company's shine is the propensity of management for excessively promotional communications with shareholders. During an investor webcast on January 5th, the company played a series of audio testimonials from patients using PRO 140 for HIV treatment, backed by tear-jerking music, and replete with emotional language devoid of data.

Worse, the company's phone number at the bottom of press releases includes an extension for Mike Mulholland, the CFO, and Nader Pourhassan, the CEO, but neither one is a "valid extension" according to the automated system.

That's the kind of approach that the FDA and SEC view unfavourably, and is likely at least in part the reason for their continued underdog status at both agencies.

The company has also become unresponsive to requests for interviews, and so with the story coming out under only these ill-advised publicity stunts, shorts are attracted, and big money investors, alienated.

But think of this "management discount" as the opportunity to acquire a sizable position (should one be so inclined) in what could very well turn out to be, in a matter of weeks, as the leading treatment for severe COVID19 related illness.

I expect the data from the trial now concluded for just such an indication could launch the company into a whole new valuation altitude that will allow it to overcome these shortfalls.

Average trading volume is steady above 6 million shares a day, and before the end of this week, we'll know just how effective leronlimab/PRO 140/Vyrologix is at saving lives from the worst of COVID 19. If the results are positive, this could be a big winner.

But if not, probably not worth holding in view of the persistent dilution.

The post Cytodyn Phase 2b/3 Trial Results Expected Any Day appeared first on Wealthpress.

Is Gold in the Middle of Consolidation? A Complete Market Analysis

Posted: 04 Feb 2021 09:49 AM PST

We noticed that gold has been trading in a pretty tight channel since last year and it looks to be entering a consolidation zone.

So we did some digging.

When looking at the gold futures market, we like to use the daily chart because the larger time frame helps us understand the next direction the gold market could move.

And if you look back at the past nine months on the chart, you'll see that gold has made FIVE u-turns… and it's in the middle of No. 6.

If gold maintains this current pattern, then, in theory, investors should expect an upward push soon.

Depending on where gold closes, we could see a bearish move to previous support levels… But if gold breaks resistance, we could see it breaking the channel and creating a new one.

The post Is Gold in the Middle of Consolidation? A Complete Market Analysis appeared first on Wealthpress.

Why Investors Shouldn’t Use Stop-Loss Orders When trading Options

Posted: 04 Feb 2021 09:46 AM PST

Proverbial Wall Street wisdom dictates that putting stop-loss orders on options is the best way to protect yourself when the stock market turns against you.

Stop-loss orders are designed to buy or sell a security when the stock moves past a predetermined exit/entry price point. Once the stop-loss order is triggered, it becomes a market order and the investor is given the lowest price on the market for the stock.

For example, many traders use stop-loss orders to protect their gains. After a stock price rises from $10 to $20, they may set a stop-loss order to sell if the stock drops below $17. That way, they don't have to closely monitor the stock's movement, but can still feel confident that if the stock's price starts dropping, they won't lose their whole profit.

While this method can limit the amount a trader will lose, this technique isn't always the most profitable in a fast-moving market…

STOP Putting Stop-Loss Orders on Options

For today’s video, I want to cover how to use stop-loss orders on options.

I'm sure you've heard by now that the proper and smart way to protect yourself from losing too much money on a trade is by using a stop-loss order. 

While you should always be practicing proper risk management, I think that using stop losses while trading options is for losers.

Here's why: The other day I had long calls on a stock, and the calls were down about 40% from where I bought them. A few days later — when I was thinking about closing out of the calls and just taking the loss — the stock market rallied up about 30% on news.

The same options that I was considering closing out of went up fourfold… and I ended up making a boat-load of money.

If I had set up any stop losses a few days prior, I would definitely be kicking myself right now because they would have closed my position right before it turned into a big win.

If you're using proper risk management — and you know you have a certain amount of money you can risk even if everything goes wrong — then you don't need to put stop losses in place when trading options.  

In fact if you are using stop-loss orders on options or thinking about it, then the chances are you're doing this wrong…

Make sure to watch my video below to learn why traders shouldn't use stop-loss orders on options and how it can ruin their trading. As always, leave your thoughts in the comments section below and don't forget to subscribe to my YouTube channel to stay up to date with all things options trading.

P.S. After watching my video about using stop-loss orders on options, read this:

Most traders don't know this… but traditional investing research is becoming obsolete. 

And that means the hours and hours you've spent studying stock charts and squinting at spreadsheets is a massive waste of your time.

You need a new way to level the playing field against Wall Street and its lightning-fast trading activity — without putting your entire portfolio at risk.

My Weekly Blitz Alert can help you do just that. 

In it, I show everyday investors just like you how they can capture predictable profits with trades that could pay out overnight. 

Don't miss your chance to collect these 24-hour windfalls!

Click Here To Watch Me Reveal My Top Trading Secret

The post Why Investors Shouldn't Use Stop-Loss Orders When trading Options appeared first on Wealthpress.

Pot Stocks Are Back in a BIG Way. Try This Under-the-Radar Name

Posted: 04 Feb 2021 09:01 AM PST

The cannabis sector has been on quite a tear the past few months. I talked about my three favorite pot stocks in the wake of the Georgia Senate run-offs back in early January. But there are always new opportunities popping up… 

And my research has led me to an under-the-radar pot stock I'd like to discuss today. 

With the federal government's legislative body becoming more favorable to the cannabis sector, it should have more solid footing for legalization.

The three stocks I discussed in January are Aphria Inc. (Nasdaq: APHA), Canopy Growth Corp. (Nasdaq: CGC) and Trulieve Cannabis Corp. (OTCMKTS: TCNNF).  

APHA is up over 90% after a proposed merger with Tilray Inc. (Nasdaq: TLRY), CGC is up about 45% and TCNNF is up about 10% after a big run up the past year. 

These three names should be familiar to most cannabis investors and I expect them to keep moving higher… But what about an under-the-radar pot stock?

An Under-the-Radar Pot Stock With Big Upside

mailbag under the radar pot stock GameStop and WallStreetBets is moderna still a buy the next GameStop SPAC trading strategy what I look for in a SPAC investment cheap oil stocks cruise line stock prices pot stocks for 2021 Moderna stock forecast Nvidia's P/E ratio Apple EV drone stocks to watch solar energy stocks invest during a stock market bubble Airbnb ipo top drone-maker stocks mailbag drugstore stocks next stock market crash rising energy stocks printing company stocks patience equals profit in the stock market passenger drone stock The same old tech and this year's work-frstocks to buy on vaccine news renewable energy stock Postelection Rally Stocks

WealthPress’ Jeff Yastine

My new company started off creating a successful business growing greenhouse veggies, and it is one of the largest indoor produce growers in America. Now it's pivoting toward cannabis as a new, more valuable crop to put under those same greenhouse roofs. 

While the bigger names I mentioned already have future growth baked into their share prices, this under-the-radar pot stock has yet to fully price in its potential growth. This stock chart over the past couple of years shows a fair amount of volatility. 

But most of that volatility is to the upside. It tripled in 2017, backtracked and then had a gigantic move higher in 2018, from $3 to $16 a share. Pot stocks mostly tanked through big parts of 2019 and 2020, and it retraced all of its gains. 

Since bottoming out amid the early days of the pandemic… when virtually everything was crashing… the shares are once again up about five-fold. 

So check out my short video and let's chat about my under-the-radar pot stock, which is trading under $15 a share. What are your favorite pot stocks? Let us know in the comments below. 

And as always, send your investing questions to jeff@yastine.com. Be sure to subscribe to my new YouTube channel. You can also follow me on  Twitter and Facebook.

P.S. Where Are Billionaires Putting Their Money?

Have you ever seen what happens when millions of dollars pour into random stocks?

For example, billionaire George Soros bought 2.7 million shares of Peloton and its share price shot from $18 to almost $140! That’s a 690% jump just from ONE man pouring some of his massive wealth into a random stock. 

But this wasn't a one-time occurrence…

You see, stock market expert Adam Sarhan seems to have found a way to tell when billionaire moguls could buy into seemingly random stocks. 

Learn Where Billionaires Are Putting Their Money

The post Pot Stocks Are Back in a BIG Way. Try This Under-the-Radar Name appeared first on Wealthpress.

The Fastest-Gaining Stocks To Watch Out for Right Now

Posted: 04 Feb 2021 07:13 AM PST

Global stock markets are mixed this morning as concerns over more U.S. economic aid, company earnings reports and bumpy trading action in various technology stocks continue to drive the markets right now. 

It's also evident that the rollout of COVID-19 vaccines is starting to take a toll on investors' minds since they haven't been distributed in some parts of Asia, which is where this all started in the first place. 

What did I tell you guys about a month ago…?

In Washington, Republicans and Democrats still aren't in agreement on passing President Joe Biden's $1.9 trillion economic stimulus package. However, many people think Democrats will look into a budget reconciliation to push Biden's plan through Congress. 

In today's video, I have more on whether the bond market is set to drop or rally… how to determine bullish and bearish bias in the Dow Jones… which big report to watch out for today… the fastest-gaining stocks in the S&P 500… and the fastest-gaining stocks in the Nasdaq 100. 

 

P.S. If you've ever wanted to know how the "smart money" operates, former Wall Street insider Jeff Zananiri has you covered. 

Jeff is revealing a little-known market secret that Wall Street consistently profits from. And once you know about it, you'll never trade the same way again. 

This trading event is so powerful, it has given Jeff's readers the chance to make a wide range of double- and triple-digit winners month after month. 

But don't just take my word for it. 

Click here to get all the details now… and learn Wall Street's secrets for yourself.

The post The Fastest-Gaining Stocks To Watch Out for Right Now appeared first on Wealthpress.

Stock Market Recap: Wednesday, Feb. 3, 2021

Posted: 03 Feb 2021 01:59 PM PST

Wall Street was choppy before closing mostly higher following solid earnings from the Tech sector — and more in Wednesday's stock market recap. 

The gains have the major indexes on the brink of setting another round of fresh all-time highs ahead of Friday's key jobs report.

Stock Market Recap

The Russell 2000 rose 0.4% after trading to a late-day high of 2,163.

stock market recap

The S&P 500 was up 0.1% with the intraday peak hitting 3,847.

stock market recap

The Dow also edged up 0.1% following the afternoon run to 30,793.

stock market recap

The Nasdaq slipped 0.02%, despite tagging a morning high of 13,723.

stock market recap

Energy and Communication Services were the strongest sectors with gains of 4.4% and 1.4%, respectively. Healthcare and Consumer Discretionary paced sector laggards after falling 0.8% and 0.6%.

Stock Market Movers

Shares of GW Pharmaceuticals PLC (Nasdaq: GWPH) skyrocketed nearly 45% after Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) announced an agreement to acquire the company for $220 per share in cash and stock for a total consideration of $7.2 billion. 

The acquisition highlights GW Pharmaceuticals' focus on prescription cannabidiol, or CBD products.

stock market recap

Stock Market Outlook 

Polo Ralph Lauren Inc. (NYSE: RL) will announce quarterly numbers ahead of Thursday's opening bell. The company is expected to report a profit of $1.63 a share on revenue of $1.47 billion. The high estimate is at $2.16 a share with the low forecast at 84 cents a share. This would equate to a 63-cent beat or a 79-cent miss.

Over the past four quarters the company has beaten forecasts by 54 cents, missed by -10 and 28 cents, while topping estimates by 41 cents in the year-ago period. There are 21 analysts that cover the stock with one Buy rating, 19 Holds, and one Underperform recommendation.

The chart shows the stock recently holding its 50-day moving average and a better-than-expected quarter could get analysts off the sidelines.

stock market recap

Global Economy

From the global stock market recap, European markets were mixed.

The Belgium20 was up by 0.9% and Germany’s DAX 30 gained 0.7%. The Stoxx 600 added 0.3%. The UK's FTSE 100 slipped 0.1% and France's CAC 40 was down less than a point.

Asian markets closed higher despite news the private gauge of China’s services-sector activity dropped in January.

South Korea's Kospi jumped 1.1% while Japan's Nikkei gained 1%. Australia's S&P/ASX 200 rose 0.9% and Hong Kong’s Hang Seng edged up 0.2%. China’s Shanghai declined 0.5%. 

Caixin China services purchasing managers index fell to 52 in January from 56.3 in December. However, the index still stood above the 50-mark — separating expansion from contraction for the ninth-straight month.

U.S. Economy

MBA Mortgage Applications rose 8.1%, following the prior week’s -4.1% decline. Nearly all of the recovery was in the refinancing index, which jumped 11.4% after a pullback of -5%. The purchase index edged up 0.1% after falling -4% previously. The pace of activity slowed on a 12-month basis, with the application index dropping to 44% year-over-year versus the prior 56.8% pace, with refis at a 59.5% year-over-year rate compared to 83.4%. The 30-year fixed rate declined to 2.92% after inching up to 2.95% previously. The five-year ARM rose to 2.88% from 2.60% previously.

ADP Employment Report revealed private payrolls rebounded 174,000 in January, versus the 78,000 decline in December. Most of the recovery was in the service sector where employment increased by 156,000, with the goods sector adding 19,000 workers. Education/health jobs rose 54,000, with a 40,000 gain in professional/business services, while leisure/hospitality added 35,000. Trade/transport employment increased 16,000 and construction gained 18,000.

Stock Market Sentiment

The iShares 20+ Year Treasury Bond ETF (Nasdaq: TLT) fell for the second straight session following the pullback to $149.58. Prior and upper support at $150-$149.50 failed to hold. A close below the latter would signal additional weakness towards $148.50-$148 and levels from last March.

Lowered resistance is at $150.50-$151.

stock market recap

Volatility Index

The iPath S&P Vix Short-Term Futures (NYSEArca: VIX) extended its losing streak to three sessions after closing on the session low of 22.91, back below the 50-day moving average. Prior and upper support at 23-22.50 were recovered. A move back below the latter would signal additional weakness towards 21.50-21.

Lowered resistance is at 24.50-25, followed by 27-27.50 and the 200-day moving average.

stock market recap

Stock Market Analysis

The SPDR S&P 500 ETF (NYSE: SPY) was up for the third straight session after trading to an intraday high of $383.70. Near-term and lower resistance at $383.50-$384 was cleared but held. A close above the latter would indicate a continued run towards $385-$385.50 with the current all-time peak at $385.85.

Rising support is at $380.50-$380.

RSI is showing signs of leveling out with lower resistance at 55-60 getting cleared and holding. A close above the latter would suggest additional strength towards 65-70. Support is at 50-45.

stock market recap

Sector

The iShares MSCI Emerging Markets ETF (NYSE: EEM) extended its winning streak to three sessions after tagging an intraday peak of $55.95. Current and lower resistance at $55.50-$56 was reclaimed. A move above the latter would be an ongoing bullish signal for additional strength towards $56.50-$57 with the current all-time high at $56.54.

Support is at $55-$54.50.

RSI is in an uptrend with key resistance at 60 getting cleared and holding. Continued closes above this level would indicate strength towards 65-70. Support is at 55-50.

stock market recap

Check back after the closing bell for the most important news and numbers in the WealthPress stock market recap. 

The post Stock Market Recap: Wednesday, Feb. 3, 2021 appeared first on Wealthpress.

3 Small-Cap Stocks To Help Boost Your Portfolio in 2021

Posted: 03 Feb 2021 12:42 PM PST

Everyone and their mother has been talking about GameStop and other small-cap stocks lately…

That makes sense because GameStop is the first of many stocks targeted by a group of small retail investors that sent the stock from it's normal $18 to $20 per share to an unheard price of $500. 

While I recommend you to stay away from short-squeeze stocks, there is a lot to be said about small caps right now. 

And I've found three small-cap stocks showing major upside potential I want to bring to your attention… 

3 Small-Cap Stocks Showing Major Upside Potential 

In case you didn't already know, small-cap stocks have been leading large caps since October, when the market digested the first presidential debate. That's especially true for the Russell 2000, an index made up of the smallest 2,000 small-cap companies. 

Smaller stocks have less correlation to the broader market because there's less institutional exposure to hedge and mutual funds when the company retains a small market cap, or the total value of all a company's shares of stock. 

The current political climate also favors smaller stocks over large caps because larger companies are under threat of overregulation under President Joe Biden's administration. In fact, smaller stocks are often provided tax breaks and potentially more stimulus.

It depends on the industry of course, so don't get too excited. 

But as far as today's video goes, I thought I'd give away three small-cap stocks showing major upside potential over the next few quarters. 

What's better than that?! 

Remember, there's less correlation between smaller stocks and the overall market. That means the level of diversification increases substantially because most small-cap stocks don't just blindly follow the market like you'd typically see with the S&P 500 and Dow Jones. 

Check out my short video and let's get into the three small-cap stocks showing major upside potential. Don't forget to subscribe to my new YouTube channel if you haven't already and like this video if you found it helpful. 

 

The post 3 Small-Cap Stocks To Help Boost Your Portfolio in 2021 appeared first on Wealthpress.

Low-Hanging Fruit: Simple Stock Picks for 2021

Posted: 03 Feb 2021 11:27 AM PST

It seems the short-squeeze hype is dying down, and those stocks are all taking a dive. Instead of leaving you holding the bag, WealthPress Head Trader Roger Scott and I have some simple stock picks for you.

Don't overthink it.

On Monday, I discussed how the GameStop Corp. (NYSE: GME) short squeeze was not a simple case of everyday traders banding together. This was an orchestrated plan by pros who probably had inside information.

And guess what? The masterminds behind it are the only ones who profited.

I would caution people to be careful of giving into FOMO with this. Massive short squeezes like GameStop's aren't consistent ways to make money. Look for value and simple stock picks.

So let's move on and look at the stock market right now. 

Don't Overthink These Simple Stock Picks for 2021

COVID-19 still exists, but the stock market is looking far ahead still.

Last year, we saw lines out the door of people trying to buy toilet paper. Then we saw stay-at-home stocks take off at incredible rates.

Now they're not doing so well. That could be because they got too hot, but the stock market seems to be predicting normalcy.

If 2020 taught us anything, it's that you can never know what's going to happen. And I don't like trying to predict the future, I like simple stocks that are going to make money.

And those exist. There are several sectors that are ready to go regardless of how long this pandemic lasts.

Stocks like Workhorse Group Inc. (Nasdaq: WKHS) are in a perfect position. With President Joe Biden wanting to replace the government fleet with electric trucks from an American company, Workhorse is the only company that qualifies. A simple stock pick.

Cannabis is in a great spot as well with the Democratic administration likely to federalize it.

If you're like me, you'll want to keep your trades simple. Check out Roger's and my video on some simple stock picks for 2021 and get up to date on the markets in our mid-week roundtable.

Feel free to send your trading questions to jeff@joyofthetrade.com and make sure to subscribe to my YouTube channel.

P.S. Did you know that, for over a century, there have been cash floods offering regular folks the chance to make gains of 20%, 40% and even 100% or more on their trades? 

These predictable money patterns happen at the start of every month, and when tapped properly, the people who know about them can make an absolute killing. 

I predict that these anomalies will continue to occur in the market for decades to come — and I know the secret to consistently profiting from them.

The post Low-Hanging Fruit: Simple Stock Picks for 2021 appeared first on Wealthpress.
Posted by: at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)